Patents Assigned to Janssen Pharmaceuticals, Inc.
-
Patent number: 11266627Abstract: The disclosure provides methods for treating major depressive disorder in a human patient having moderate or severe anhedonia. The methods comprise administering to the patient in need thereof an effective amount of aticaprant, or a pharmaceutically acceptable salt thereof. In some embodiments, the patient had an inadequate response to other antidepressant therapy prior to treatment with aticaprant. In other embodiments, the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.Type: GrantFiled: May 4, 2021Date of Patent: March 8, 2022Assignee: Janssen Pharmaceuticals, Inc.Inventors: Mark Schmidt, Vanina Popova, Adam Savitz, Rama Melkote, Wayne C. Drevets, Srihari Gopal, Darrel Pemberton, Chakradhar Lagishetty, Iva Kezic
-
Patent number: 11214600Abstract: Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Coagulase (Coa). Further aspects relate to immunogenic compositions comprising at least one Staphylococcal coagulase R Domain, wherein the R Domain is 80% identical in sequence to a R Domain.Type: GrantFiled: February 10, 2017Date of Patent: January 4, 2022Assignees: The University of Chicago, Janssen Pharmaceuticals, Inc.Inventors: Dominique Missiakas, Olaf Schneewind, Carla Emolo, Lena Thomer, Molly McAdow, Jeroen Geurtsen, Mark De Been
-
Publication number: 20210395745Abstract: Described are methods for inhibition of Hepatitis B virus gene expression or treating symptoms and/or diseases associated with Hepatitis B virus infection. Dosing regimens for administering these RNAi agents are also described. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.Type: ApplicationFiled: August 6, 2021Publication date: December 23, 2021Applicants: Arrowhead Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc.Inventors: Bruce D. GIVEN, James C. HAMILTON, Thomas SCHLUEP, Maria Gloria BEUMONT, Oliver LENZ, Ronald Cornelis Marie KALMEIJER
-
Patent number: 11180450Abstract: The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: June 5, 2020Date of Patent: November 23, 2021Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit LeuvenInventors: Bart Rudolf Romanie Kesteleyn, Pierre Jean-Marie Bernard Raboisson, Jean-François Bonfanti, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
-
Patent number: 11179368Abstract: The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: March 29, 2018Date of Patent: November 23, 2021Assignees: JANSSEN PHARMACEUTICALS, INC., KATHOLIEKE UNIVERSITEIT LEUVENInventors: Dorothée Alice Marie-Eve Bardiot, Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Pierre Jean-Marie Bernard Raboisson, Arnaud Didier M Marchand
-
Patent number: 11155637Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.Type: GrantFiled: June 26, 2019Date of Patent: October 26, 2021Assignee: Janssen Pharmaceuticals, Inc.Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
-
Publication number: 20210300868Abstract: The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.Type: ApplicationFiled: May 28, 2021Publication date: September 30, 2021Applicants: Janssen Pharmaceuticals, Inc., Katholieke Universiteit LeuvenInventors: Jean-François Bonfanti, Bart Rudolf Romanie Kesteleyn, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand, Erwin Coesemans, Benoît Christian Albert Ghislain De Boeck, Pierre Jean-Marie Bernard Raboisson
-
Publication number: 20210290855Abstract: A grip accessory for a manual injection device comprises a housing having a generally hollow body for supporting a manual injection device therein. The housing comprises a distal portion comprising a first opening into which a manual injection device can be inserted, a proximal portion comprising a second opening through which a needle of the manual injection device is extendable, the proximal portion comprising a skin contacting surface at a proximal end of the device. An intermediate portion extends between the proximal and distal portions and guide means is provided on an interior surface of the distal portion for guiding a plunger rod of an injection device during delivery of an injection.Type: ApplicationFiled: May 29, 2018Publication date: September 23, 2021Applicant: Janssen Pharmaceuticals, Inc.Inventors: James McLUSKY, Nick FOLEY, Jimmy MOWER, Ian SCRIMGEOUR, Michael CANNAMELA, Peter KRULEVITCH, Kui LIU
-
Patent number: 11124552Abstract: Liposomes containing tau peptides, preferably phosphorylated tau peptides, and conjugates containing tau peptides, preferably phosphorylated tau peptides, conjugated to an immunogenic carrier are described. Pharmaceutical compositions and uses of the liposomes and/or conjugates for treating or preventing a neurodegenerative disease or disorder, such as Alzheimer's Disease, are also described.Type: GrantFiled: October 24, 2018Date of Patent: September 21, 2021Assignees: AC Immune SA, Janssen Pharmaceuticals, Inc.Inventors: Elizabeth Anne Ramsburg, Donata De Marco, Charlotte Sadaka, Jaap Goudsmit, Andreas Muhs, Maria Pihlgren Bosch, Marija Vukicevic Verhille, Nicolas Piot, Saroj Raj Ghimire
-
Patent number: 11083707Abstract: The present invention relates to substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: March 29, 2018Date of Patent: August 10, 2021Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit LeuvenInventors: Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Erwin Coesemans, Pierre Jean-Marie Bernard Raboisson, Arnaud Didier M Marchand, Dorothée Alice Marie-Eve Bardiot
-
Patent number: 11083786Abstract: The present disclosure generally relates to the use of different self-amplifying RNA molecules to enhance immune responses, for example immune responses following prophylactic vaccination or therapeutic administration. Some embodiments relate to compositions and methods for inducing an immune response in a subject using prime-boost immunization regimens.Type: GrantFiled: January 18, 2019Date of Patent: August 10, 2021Assignee: JANSSEN PHARMACEUTICALS, INC.Inventors: Kurt Iver Kamrud, Nathaniel Stephen Wang, Parinaz Aliahmad, Jason DeHart
-
Patent number: 11071729Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.Type: GrantFiled: October 14, 2019Date of Patent: July 27, 2021Assignees: Addex Pharmaceuticals S.A., Janssen Pharmaceuticals, Inc.Inventors: Jose Maria Cid-Nunez, Andres Avelino Trabanco-Suarez, Gregor James MacDonald, Guillaume Albert Jacques Duvey, Terry Patrick Finn
-
Patent number: 11053196Abstract: The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: May 18, 2018Date of Patent: July 6, 2021Assignees: Janssen Pharmaceuticals, Inc., Kathalieke Universiteif LeuvenInventors: Jean-François Bonfanti, Bart Rudolf Romanie Kesteleyn, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand, Erwin Coesemans, Benoît Christian Albert Ghislain De Boeck, Pierre Jean-Marie Bernard Raboisson
-
Patent number: 11033633Abstract: Compositions and methods for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) are described. In particular, multivalent vaccines containing O-antigen polysaccharide covalently bound to an exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein that can withstand multiple environmental stresses are described.Type: GrantFiled: December 10, 2019Date of Patent: June 15, 2021Assignee: JANSSEN PHARMACEUTICALS, INC.Inventors: Olga Labovitiadi, Wouter Frank Tonnis, Francesco Doro, Janik Adriaansen
-
Publication number: 20210171462Abstract: The present invention relates to mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using the compounds and also relates to use of the compounds as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.Type: ApplicationFiled: December 31, 2020Publication date: June 10, 2021Applicants: Janssen Pharmaceuticals, Inc., Katholieke Universiteit LeuvenInventors: Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
-
Patent number: 10919854Abstract: The present invention relates to mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using the compounds and also relates to use of the compounds as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: May 13, 2020Date of Patent: February 16, 2021Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit LeuvenInventors: Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
-
Patent number: 10913716Abstract: The present invention concerns substituted indoline compounds, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: March 31, 2017Date of Patent: February 9, 2021Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit LeuvenInventors: Bart Rudolf Romanie Kesteleyn, Pierre Jean-Marie Bernard Raboisson, Jean-François Bonfanti, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
-
Patent number: 10864263Abstract: Provided are methods for generating an immune response against a Zika virus in a human subject in need thereof. The methods comprise administering to the subject a pharmaceutical composition comprising adenoviral vectors encoding a Zika virus antigen and a pharmaceutically acceptable carrier.Type: GrantFiled: November 19, 2018Date of Patent: December 15, 2020Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center. Inc.Inventors: Dan Barouch, Macaya Julie Douoguih, Gaston Rafael Picchio
-
Patent number: D946141Type: GrantFiled: March 15, 2019Date of Patent: March 15, 2022Assignee: Janssen Pharmaceuticals, Inc.Inventors: Peter Krulevitch, Michael Cannamela, Yuji Ikeda, Nick Foley, James McLusky, Jimmy Mower, Scott Martin, James Glencross
-
Patent number: D946750Type: GrantFiled: January 9, 2019Date of Patent: March 22, 2022Assignee: Janssen Pharmaceuticals, Inc.Inventors: James McLusky, Nick Foley, Jimmy Mower, Michael Cannamela, Peter Krulevitch, James Flint